Can a targeted pill boost Chemo's power against a rare blood cancer?

NCT ID NCT07725705

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial is testing whether adding an experimental targeted drug, SHR2554, to standard chemotherapy (liposomal mitoxantrone) can improve outcomes for people with peripheral T-cell lymphoma (PTCL) who have not yet been treated. The study involves about 44 adults with certain PTCL subtypes. Researchers are looking at safety and how well the combination shrinks tumors, with the possibility of maintenance therapy for those who respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an EZH2 inhibitor called SHR2554 combined with liposomal mitoxantrone
What this could lead to: If successful, this combination could offer a new first-line treatment option for peripheral T-cell lymphoma, potentially improving response rates and outcomes.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

enteropathy-associated T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma monomorphic epitheliotropic intestinal T-cell lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST LINE TREATMENT PTCL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.